Bio-Rad Laboratories (BIO) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
10x Genomics (TXG) has outperformed Bio-Rad Laboratories (BIO) over the past year, gaining 556.0% versus a gain of 24.1%. Over five years, BIO leads with a -49.0% price change compared with -50.0% for TXG. 10x Genomics is the larger company by market cap ($9.92 billion vs $9.84 billion), about 1.0 times the size.
On valuation, Bio-Rad Laboratories trades at a lower forward P/E (37.1x vs 992.6x for 10x Genomics). Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus -6.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO | TXG |
|---|---|---|
| Share price | $367.92 | $76.10 |
| Market cap | $9.84B | $9.92B |
| 1-day change | -0.25% | -5.65% |
| YTD return | +21.43% | +366.58% |
| 1-year return | +24.08% | +556.03% |
| 5-year return | -49.00% | -50.02% |
| P/E ratio (TTM) | 46.63 | — |
| Forward P/E | 37.10 | 992.57 |
| EPS (TTM) | $7.89 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | $642.82M |
| Revenue growth (YoY) | +0.65% | +5.25% |
| Net income (latest FY) | $759.90M | $-43.54M |
| Gross margin | 51.87% | 69.05% |
| Operating margin | 1.83% | -9.49% |
| Net margin | 29.42% | -6.77% |
| 52-week high | $396.23 | $102.81 |
| 52-week low | $236.73 | $11.16 |
| Distance from 52-week high | -7.14% | -25.98% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -10.76% | -13.27% |
| Average volume | 276.94K | 3.15M |
| Shares outstanding | 21.68M | 120.21M |
| Employees | 7,450 | 1,178 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TXG has outperformed BIO by 532.0 percentage points over the past year.
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -6.8 cents for 10x Genomics.
About Bio-Rad Laboratories
BIO stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees
BIO vs TXG FAQ
Which is bigger, Bio-Rad Laboratories or 10x Genomics?
10x Genomics (TXG) is larger, with a market capitalization of $9.92B compared with $9.84B for Bio-Rad Laboratories (BIO).
Which stock has performed better over the past year, BIO or TXG?
TXG returned +556.03% over the past 12 months, compared with +24.08% for BIO (price return, excluding dividends). Past performance does not predict future results.
Are Bio-Rad Laboratories and 10x Genomics in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.